WASHINGTON — Forget the push to bring more generics to market or to tweak Medicare’s arcane payment system.

Democrats, newly empowered in D.C. and on the hunt for bigger and bolder ways to lower drug prices, are suddenly taking aim at a far more central part of pharma’s monopoly power: the patents the industry holds on its drugs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The author unfortunately refers to “legislation that could end drug company monopolies,” which is just the sort of hyperbole that PhRMA feeds on. These proposals would not “end” monopolies, but rather regulate the use of — and combat the abuse of — monopolies. As we do in other sectors where monopolies exist. These are sensible proposals that should be debated. The US is virtually the only country that grants the patent (i.e. monopoly) and then allows the patent-holder (monopolist) to charge whatever price it wants.

  • It looks like these journalists/marketers did not look at the latest alternative facts coming from HHS. According to industry insiders at HHS lower pharmaceutical prices lead to socialism. In Alternate Fact America, this kind of market industry fluff continues to add to the death toll, as people die in the Epidemic of Despair.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy